9m 수평낙하 시 핵연료봉 피복관의 파괴 거동 분석

강새한솔(Sae-Han-Sol Kang),김동현(Dong-Hyun Kim),장윤석(Yoon-Suk Chang) 대한기계학회 2019 대한기계학회 춘추학술대회 Vol.2019 No.4

사용후핵연료 운반·저장용기 낙하시 구조해석 방법 검증

강새한솔(Sae-Han-Sol Kang),한상민(Sang-Min Han),장윤석(Yoon-Suk Chang),이상환(Sang-Hwan Lee) 대한기계학회 2020 대한기계학회 춘추학술대회 Vol.2020 No.12

금속 전기비저항의 정밀측정에 관한 연구

강전홍(Kang Jeon Hong),유광민(Yu Kwang Min),김한준(Kim Han Jun),한상옥(Han Sang Ok),박강식(Park Kang Sic),이세현(Lee Sae Hun) 대한전기학회 2007 대한전기학회 학술대회 논문집 Vol.2007 No.4

금속의 전기 비저항 측정방법은 일반적으로 4단자, van der Pauw, Four-Point Probe(FPP), eddy current 방법 등이 있다. 이들의 측정방법들은 각각 다르지만 동일한 시료에 대한 전기 비저항 측정값은 거의 같은 결과를 나타내어야 한다. 금속 전기 비저항의 정밀측정에 대한 연구를 위하여 비자성 금속인 STS 316 시료를 선정하여 측정한 결과 4단자와 van der Pauw 방법으로 측정된 비저항은 각각 75.86 ㎕ · ㎝(2.273 %IACS), 75.80 ㎕ · ㎝(2.275 %IACS)이며, 측정 불확도는 0.25 %로서 거의 동등한 결과를 나타냈고, Four Point Probe(FPP) 방법으로 측정된 비저항은 75.36 ㎕ · ㎝(2.288 %IACS), 측정 불확도는 0.45 %, eddy current 방법으로 측정된 비저항은 76.63 ㎕ · ㎝(2.25 %IACS), 측정 불확도는 0.64 %로 나타났다.

개심술시 혈액 응고 인자의 변화

한승세,이성행,강덕식 慶北大學校 醫科大學 1982 慶北醫大誌 Vol.23 No.2

경북의대 흉부외과학 교실에서 1982년도에 개심술을 시행한 환자 중 무작위로 10예를 선택하여 혈액응고인자를 검사한 바 다음과 같은 성적을 얻었다. 혈액응고인자 즉 Ⅰ,Ⅱ,Ⅴ, 및 Ⅷ의 활성치는 모두 관류초기 및 관류말기에 심한 감소를 보였고 (p<0.001) 관류후 2-4시간에 대조치인 전신마취 중의 검사치로 회복하는 추세를 보였다. 술후 출혈량은 517±329ml/M^2/day 였으며 결론적으로 관류중 혈액응고인자의 심한 감소현상이 술후 비교적 빠른시간내에 관류전치로 회복하고 있는 것으로 보아 술후 과도한 출혈의 중요한 원인이 되지는 않는 것으로 본다. This study was performed to analyze the magnitude and duration of changes in certain clotting factors during and following cardiopulmonary bypass and to correlate these changes with excessive bleeding, if it occurred. Ten cases of patients were randomly selected for this study. They were examined factor assays such as Ⅰ,Ⅱ,Ⅴ, and Ⅷ, using a Coag-stat BC-2210 Blood Coagulation Analyzer. Blood samples were obtained during general anesthesia, at the beginning of the bypass, at the end of bypass and 2-4 hours after bypass. Factor activities such as Ⅰ,Ⅱ,Ⅴ, and Ⅷ decreased markedly during bypass(p<0.001) and returned promptly to control levels which are values during general anesthesia at 2-4 hours after bypass. Postoperative bleeding presented as 517±329ml/M^2/day.

Epithelial and mesenchymal circulating tumor cell isolation and discrimination using dual-immunopatterned device with newly-developed anti-63B6 and anti-EpCAM

Kang, Yoon-Tae,Kim, Young Jun,Bu, Jiyoon,Chen, Shilin,Cho, Young-Ho,Lee, Hyun Min,Ryu, Chun Jeih,Lim, Yoojoo,Han, Sae-Won Elsevier 2018 Sensors and actuators. B Chemical Vol.260 No.-

<P><B>Abstract</B></P> <P>We report a dual-immunopatterned microfluidic device for capturing both epithelial and mesenchymal circulating tumor cells (CTCs) simultaneously in a single device using the two antibodies of anti-epithelial cell adhesion molecule (EpCAM) antibody and newly developed anti-63B6 antibody. In addition to the conventional epithelial antibody of anti-EpCAM, our in-house produced anti-63B6 antibody targets mesenchymal stem cell-like cancer cells and intermediate cancer cells, thus overcoming limitation of the conventional single anti-EpCAM based CTC isolations. These two antibodies are immobilized to each top and bottom layer of the present device and the combination of two layers forms a circular chamber with the center inlet. The mutual complementary cell isolation through competing reaction in different velocity zones between mesenchymal and epithelial antibodies enables the precise screening and profiling of CTCs depending on their positivity and degree of epithelial/mesenchymal surface antigen expression, which may differ in compliance with disease status.</P> <P>From the experiments using epithelial and mesenchymal-like cancer cells, the present device captures 94.47% of cancer cells, which is substantially higher than the EpCAM-only-based method in terms of heterogeneous cancer cell isolation including mesenchymal–like cancer cells. Patient blood samples were employed to assess the clinical application of the present device for examining the patient status based on their CTC heterogeneity. The CTCs captured by both antibodies exhibit considerably varied expression profiles of epithelial protein including cytokeratin and EpCAM. The present device facilitates the isolation of heterogeneous subtypes of CTCs. These undiscovered heterogeneities would be helpful for precise analysis of CTCs to find their underlying meaning in cancer progression.</P> <P><B>Highlights</B></P> <P> <UL> <LI> We present a dual-immunopatterned microfluidic device for capturing both epithelial and mesenchymal circulating tumor cells. </LI> <LI> Our in-house produced anti-63B6 antibody targets mesenchymal stem cell-like cancer cells and intermediate cancer cells. </LI> <LI> This device captures 94% of epithelial and mesenchymal cancer cells, significantly higher than previous anti-EpCAM methods. </LI> <LI> Our novel antibody combination facilitates isolation of EpCAM+, EpCAM- CTCs with non-defined CTC-like (EpCAM-/CK-) cells. </LI> <LI> Heterogeneous CTCs enriched by the present device are expected to elucidate the undiscovered roles of CTCs for cancer. </LI> </UL> </P>

HCC : O-052 ; Clinical outcomes of sorafenib treatment in patients with advanced hepatocellular carcinoma: A multi-institute experience

( Sae Hwan Lee ),( Il Han Song ),( Ran Noh ),( Ha Yan Kang ),( Soon Young Ko ),( Eom Seok Lee ),( Seok Hyun Kim ),( An Na Kim ),( Byung Seok Lee ),( Hee Bok Chae ),( Hong Soo Kim ),( Young Woo Kang ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1

Backgroud/Aims: Sorafenib, an oral multikinase inhibitor with antiangiogenic and antiproliferative properties, showed significant benefits in terms of time to progression and survival in patients with advanced hepatocellular carcinoma (HCC) in large clinical trials. The aim of this study was to investigate treatment outcomes of sorafenib in real clinical fields. Methods: From August 2007 to March 2012, patients with advanced HCC who received sorafenib in seven referral hospitals in Daejeon-Chungcheong province were retrospectively enrolled for the evaluation of tolerability, treatment response and survival following sorafenib administration. Treatment response was radiologically assessed by RECIST 1.1. Results: Among a total of 123 patients enrolled, sixty-eight (55%) patients received prior treatment and 74 (60%) patients had Child-Pugh A cirrhosis. One hundred-three (84%) patients were BCLC stage C; Ninety-three (76%) patients were modified UICC IV. The median duration of sorafenib treatment was 67 (14-452) days. Seventy-three (60%) patients have experienced adverse events, resulting in transient dose reduction or cessation. Treatment interruption was brought by disease progression (36%), adverse events (21%), hepatic failure (10%), and financial burden (7%). Complete response, partial response and stable disease were seen in none, 1% and 18%, respectively, and disease control rate was 29%. Median time to progression was 84 days and overall median survival was 139 days. Patients with decompensated cirrhosis showed a shorter median time to progression (61 vs. 104 days, p=0.036) and overall survival (63 vs. 168 days, p<0.001) compared to those with compensated cirrhosis. Child-Pugh class B/C (p=0.027) and prior treatment (p=0.015) were independent risk factors for survival. Conclusions: Clinical outcomes of sorafenib treatment in patients with advanced HCC were comparable to those of previous studies. The function of hepatic reserve and history of previous treatment were independent factors affecting survival.

Histological Features Affecting Hepatocarcinogenesis in Chronic Viral Hepatitis

( Sae Hwan Lee ),( Young Hwa Chung ),( Dan Bi Lee ),( Yoon Seon Lee ),( Hyun Ju Min ),( Dong Dae Seo ),( Kang Mo Kim ),( Young Suk Lim ),( Han Chu Lee ),( Eun Sil Yu ),( Yung Sang Lee ),( Dong Jin Suh 대한간학회 2007 Clinical and Molecular Hepatology(대한간학회지) Vol.13 No.3(S)

Wideband Coupling Modeling Analysis by Arbitrarily Incoming Source Fields Based on the Electromagnetic Topology Technique

Han, Jung-Hoon,Ju, Sae-Hoon,Kang, No-Weon,Lee, Woo-Sang,Choi, Jin-Soo Professional Technical Group on Microwace Theory a 2019 IEEE transactions on microwave theory and techniqu Vol.67 No.1

<P>It is very difficult to analyze electromagnetic (EM) responses of electrically large and complex objects because this requires a large amount of computing resources or extremely long calculation times. The EM topology (EMT) technique has been developed as a potential solution to overcome this resource-consuming limitation. The EMT technique can reduce computing resource by recombining EM analysis results of physically or electrically divided subblock models, instead of an entire model. However, the EMT technique still has some shortcomings to be overcome when applied to complex electrical systems subject to arbitrarily directional incoming sources. In this paper, we propose a wideband coupling analysis method by arbitrarily incoming sources based on the EMT technique for complex waveguide structures including a printed circuit board. A topological network is proposed that takes into account the effect on arbitrarily directional incoming sources with their polarization (vertical, horizontal, and circular). Explanations and definitions of several parameters for the proposed topological network are discussed. S-parameters are obtained using the CST-MWS tool. The analysis results of the proposed method, the entire model by the CST-MWS, and measurement results from a reference paper are compared, and the validity of the approach is verified.</P>

High-purity capture and release of circulating exosomes using an exosome-specific dual-patterned immunofiltration (ExoDIF) device

Kang, Yoon-Tae,Kim, Young Jun,Bu, Jiyoon,Cho, Young-Ho,Han, Sae-Won,Moon, Byung-In Royal Society of Chemistry 2017 Nanoscale Vol.9 No.36

<P>We present a microfluidic device for the capture and release of circulating exosomes from human blood. The exosome-specific dual-patterned immunofiltration (ExoDIF) device is composed of two distinct immuno-patterned layers, and is capable of enhancing the chance of binding between the antibody and exosomes by generating mechanical whirling, thus achieving high-throughput exosome isolation with high specificity. Moreover, follow-up recovery after the immuno-affinity based isolation,<I>via</I>cleavage of a linker, enables further downstream analysis. We verified the performance of the present device using MCF-7 secreted exosomes and found that both the concentration and proportion of exosome-sized vesicles were higher than in the samples obtained from the conventional exosome isolation kit. We then isolated exosomes from the human blood samples with our device to compare the exosome level between cancer patients and healthy donors. Cancer patients show a significantly higher exosome level with higher selectivity when validating the exosome-sized vesicles using both electron microscopy and nanoparticle tracking analysis. The captured exosomes from cancer patients also express abundant cancer-associated antigens, the epithelial cell adhesion molecule (EpCAM) on their surface. Our simple and rapid exosome recovery technique has huge potential to elucidate the function of exosomes in cancer patients and can thus be applied for various exosome-based cancer research studies.</P>

Yeast 2 μm 플라스미드 유래 FLP recombinase 유전자의 곤충 배양세포 내 발현

강석우,윤은영,김상현,김근영,한명세,강석권 한국잠사학회 1997 한국잠사곤충학회지 Vol.39 No.1

In order to express the FLP recombinase in B. mori cultured cell line, BmN-4, transient expression system using a heat shock protein gene (hsp70) promoter of Dorosophilla melanogaster was constructed. This vector was designated as pHgSV. Activity strength of the hsp70 promoter was compared with that of immediate earHy gene (IE-1) and polyhedrin gene of BmNPV employing the E. coli ß-galactosidase gene as a reporter gene. The result showed that the pHs ß-gal plasmid vector expressed the ß-galactosidase at 2nd and 3rd day after the transfer of plasmid DNA into BmN-4 cells, which was similar to that of pIE1 ß-gal vector, but different from that of a recombinant virus, vBm ß-gal. For the construction of FLP recombinase transient expression vector, the FLP recombinase gene was cloned by polymerase chain reaction technique. To express the FLP recombinase, this gene was inserted into pHsSV plasmid vertor, under the control of the hsp70 promoter, and tranfected in BmN-4 cells. The expressed FLP recombinase was estimated at 44kDa on a 12.5% SDS-PAGE.